CompletedNCT02511886
Arbaclofen Placarbil Dose and Tolerability for Alcohol Use
About this title
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Read the official source — NCT02511886Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Oakland ParkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- Indivior Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02511886
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Oakland Park
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Indivior Inc.
Did this study involve medication?
Yes. The study involved medication, including Arbaclofen Placarbil and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
